ClinicalTrials.gg
CompletedNCT05737940Re-PHIREUpdated Oct 27, 2026Results posted

A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2

A Phase 2 interventional study of AZD3427 and Placebo in Pulmonary Hypertension (World Health Organization Group 2) and Heart Failure, sponsored by AstraZeneca. Completed at 60 sites in 14 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

How we know

Updated Oct 27, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 397 studies in Hypertension, Pulmonary with a site in United States — 72 open to participants now, 86 under way, 9 of them phase 3. Hypertension, Pulmonary · United States.

Enrollment
38th of 286
260 · median 30
Started
2023
with 14 others
Phase 2
93 of 397
13 open now
Registered
328th of 397
by date

Among the 397 studies in Hypertension, Pulmonary with a site in United States, this one is the 38th largest by enrollment of the 286 interventional ones that give a count, is one of 15 that started in 2023, is one of 93 in phase 2, and was the 328th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

72 of the 397 studies in Hypertension, Pulmonary with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 397 studies in Hypertension, Pulmonary with a site in United States, or all of them as a file.
02

Study summary

This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2

Read the detailed description

This study is a randomized, placebo-controlled, multi-centre, dose-ranging study of AZD3427 in participants with heart failure and pulmonary hypertension due to left heart disease (World Health Organisation [WHO] Group 2).

Approximately 220 participants will be randomised to 4 treatment groups (in a 1:1:1:1 ratio) to receive a subcutaneous (SC) injection of AZD3427 or placebo every 2 weeks for 24 weeks.

This study will evaluate 3 dose levels of AZD3427: Dose A, Dose B, and Dose C. Dose modification is not applicable for this study.

The study will be conducted in approximately 60 study centres across an estimated 15 countries.

The study will include approximately 16 study visits: 2 visits during the Screening Period,13 visits during the Treatment Period, and one visit during the Follow-up Period.

The expected total duration of the study is 32 to 37 weeks, depending on the length of the Screening Period.

03

Conditions studied

  • Pulmonary Hypertension (World Health Organization Group 2)
  • Heart Failure

Keywords

  • Pulmonary Hypertension
  • Heart Failure
  • Left Heart Disease
  • WHO Group 2
  • Dose-ranging Study
  • Pulmonary vascular resistance
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be ≥ 18 years of age inclusive.
  2. Participants must have a pre-existing diagnosis of HF, function class (FC) II to IV, and a pre-existing diagnosis of PH-LHD or likely or intermediate probability of Pulmonary hypertension due to left heart disease (PH-LHD) as per 2022 Pulmonary hypertension due to left heart disease European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines. Participants must be on stable HF standard of care medication, including diuretics.
  3. Participants must have a combination of echocardiographic parameters that show intermediate or high probability of PH as per 2022 ESC/ERS guidelines.
  4. Participants must have an on-study elevated pulmonary artery pressure from RHC performed as per RHC manual provided by the Sponsor, at Screening Visit 2:

    1. PAWP ≥ 15 mmHg
    2. mPAP ≥ 20 mmHg
  5. Minimum body weight of 45 kg (inclusive).
  6. Capable and willing of giving signed .

Exclusion criteria

Exclusion Criteria

  1. Diagnosis of PH in World Health Organization (WHO) Group 1, WHO Group 3, WHO Group 4, or WHO Group 5.
  2. Historical or current evidence of a disease or disorder.
  3. Decompensated HF or hospitalisation due to decompensated HF.
  4. Any to RHC.
  5. History of to SC injections or devices.
  6. History of hypersensitivity to drugs with a similar chemical structure or class to AZD3427 or any component of AZD3427 drug product, or ongoing clinically important allergy/hypersensitivity.
  7. Known lung disease with (FEV1) \< 30% of predicted.
  8. Congenital long syndrome.
  9. Cardiac ventricular arrhythmia which requires treatment. Participants with atrial fibrillation or flutter and controlled ventricular rate are permitted.
  10. History of or anticipated heart transplant or ventricular assist device implantation.
  11. Any known planned (scheduled) highly invasive Cardiovascular (CV) procedure (eg, coronary revascularisation, ablation of atrial fibrillation/flutter, valve repair/replacement, aortic aneurysm surgery, etc).
  12. Participants who have previously received AZD3427.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
260 participants (actual)

Study arms

  • Experimental
    AZD3427 Dose A

    The participants will receive single dose of AZD3427 Dose A every 2 weeks for 24 weeks from Day 1 to Day 155.

    Drug: AZD3427

  • Experimental
    AZD3427 Dose B

    The participants will receive single dose of AZD3427 Dose B every 2 weeks for 24 weeks from Day 1 to Day 155.

    Drug: AZD3427

  • Experimental
    AZD3427 Dose C

    The participants will receive single dose of AZD3427 Dose C every 2 weeks for 24 weeks from Day 1 to Day 155.

    Drug: AZD3427

  • Placebo comparator
    Placebo

    The participants will receive single dose of placebo every 2 weeks for 24 weeks from Day 1 to Day 155.

    Drug: Placebo

Interventions

  • The participants will receive AZD3427 SC injection single dose of either Dose A or Dose B or Dose C every 2 weeks for 24 weeks.

  • DrugPlacebo

    The participants will receive SC injection of placebo single dose every 2 weeks for 24 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Pulmonary Vascular Resistance (PVR)

    The effect of AZD3427 compared with placebo on PVR parameter as measured by right heart catheterization (RHC-a procedure which allows measurement of blood pressure in the right side of the heart) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2 was evaluated. PVR was calculated using formula, PVR=80\* \[Mean pulmonary arterial pressure\[mPAP\](mmHg)- Pulmonary artery wedge pressure\[PAWP\](mmHg)\]/Cardiac output (L/min). Baseline was defined as last non-missing value prior to or on the date of first study intervention dose. PVR was originally measured in dynes·sec/cm⁵. For the statistical analysis, PVR values were log-transformed, and change from baseline was assessed on the log-transformed scale. Results were subsequently back-transformed and presented on the original scale as the ratio of post-baseline to baseline PVR. Therefore, the unit of measure for this endpoint is a ratio. The measure type is geometric mean ratio.

    Time frame: Baseline to Week 25

Secondary outcomes

  1. Change From Baseline in Mean Pulmonary Arterial Pressure (mPAP)

    The effect of AZD3427 compared with placebo on mPAP parameter as measured by RHC after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

    Time frame: Baseline to Week 25

  2. Change From Baseline in Pulmonary Artery Wedge Pressure (PAWP)

    The effect of AZD3427 compared with placebo on PAWP parameter as measured by RHC after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention. PAWP was measured in mmHg. The analysis was done similar to the primary endpoint. Therefore, the unit of measure for this endpoint is a ratio. The measure type is geometric mean ratio.

    Time frame: Baseline to Week 25

  3. Change From Baseline in Cardiac Output (CO) ECHO

    The effect of AZD3427 compared with placebo on CO parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

    Time frame: Baseline to Week 25

  4. Change From Baseline in Left Ventricular Stroke Volume (LV SV)

    The effect of AZD3427 compared with placebo on LV SV parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

    Time frame: Baseline to Week 25

  5. Change From Baseline in Left Ventricular Ejection Fraction (LVEF)

    The effect of AZD3427 compared with placebo on EF parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

    Time frame: Baseline to Week 25

  6. Change From Baseline in Left Ventricular Global Longitudinal Strain (LVGLS)

    The effect of AZD3427 compared with placebo on LVGLS parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. LVGLS is measured by echocardiograohy. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

    Time frame: Baseline to Week 25

  7. Change From Baseline in Pulmonary Arterial Systolic Pressure (PASP)

    The effect of AZD3427 compared with placebo on PASP parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

    Time frame: Baseline to Week 25

  8. Change From Baseline in Right Ventricle/Left Ventricle (RV/LV) Ratio

    The effect of AZD3427 compared with placebo on RV/LV parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

    Time frame: Baseline to Week 25

  9. Change From Baseline in Right Ventricular Outflow Tract Acceleration Time (RVOT AT)

    The effect of AZD3427 compared with placebo on RVOT AT parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

    Time frame: Baseline to Week 25

  10. Change From Baseline in Tricuspid Regurgitation Velocity (TRV)

    The effect of AZD3427 compared with placebo on TRV parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. TRV was measured by Echocardiography. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

    Time frame: Baseline to Week 25

  11. Change From Baseline in TAPSE/PASP [Tricuspid Annular Plane Systolic Excursion/ Pulmonary Arterial Systolic Pressure]

    The effect of AZD3427 compared with placebo on TAPSE/PASP parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

    Time frame: Baseline to Week 25

  12. Change From Baseline in Systemic Vascular Resistance (SVR)

    The effect of AZD3427 compared with placebo on systemic vascular resistance parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. SVR was measured by Echocardipgraphy. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

    Time frame: Baseline to Week 25

  13. Change From Baseline in 6-minute Walking Distance (6MWD)

    The effect of AZD3427 compared with placebo on function and symptoms using 6MWD parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

    Time frame: Baseline to Week 25

  14. Change From Baseline in Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ TSS)

    The effect of AZD3427 compared with placebo on function and symptoms using KCCQ TSS parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. The score ranged from 0 to 100, where a higher score represents a better patient outcome. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

    Time frame: Baseline to Week 25

  15. Number of Participants With Improved Change From Baseline in New York Heart Association Functional Class (NYHA FC)

    The effect of AZD3427 compared with placebo on function and symptoms using NYHA FC parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

    Time frame: Baseline to Week 25

  16. Change From Baseline in Serum Creatinine

    The effect of AZD3427 compared with placebo using serum creatinine parameter after 12 and 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention. Creatinine was measured in micromoles/liter. The analysis was done similar to the primary endpoint. Therefore, the unit of measure for this endpoint is a ratio.

    Time frame: Baseline to Week 13 and Week 25

  17. Change From Baseline in N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP)

    The effect of AZD3427 compared with placebo using NT-proBNP parameter after 12 and 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention. NT-ProBNP was measured in picomole/Liter. The analysis was done similar to the primary endpoint. Therefore, the unit of measure for this endpoint is a ratio.

    Time frame: Baseline to Week 13 and Week 25

  18. Change From Baseline in Cystatin C

    The effect of AZD3427 compared with placebo using cystatin C parameter after 12 and 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention. Cystatin C was measured in milligram/deciliter. The analysis was done similar to the primary endpoint. Therefore, the unit of measure for this endpoint is a ratio.

    Time frame: Baseline to Week 13 and Week 25

  19. Change From Baseline in eGFR (Estimated Glomerular Filtration Rate)

    The effect of AZD3427 compared with placebo using eGFR parameter after 12 and 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

    Time frame: Baseline to Week 13 and Week 25

  20. AZD3427 Serum Concentration

    Serum concentration of AZD3427 was summarised by timepoints and dose level. This was done to evaluate the pharmacokinetics (PK) of AZD3427 after dosing in participants with HF and PH Group 2. Considering the approximately 13-14 days half-life of AZD3427, low or non-quantifiable serum concentrations at Week 31 are not unexpected. Therefore, the presentation of the Week 31 results, including the reported NA values, reflects the prespecified statistical handling of the data and the observed concentration profile.

    Time frame: On Week 3, Week 5, Week 13, Week 19, Week 25 and Week 31

  21. Number of Participants With Presence of Anti-drug Antibodies (ADAs)

    The immunogenicity of AZD3427 was evaluated as measured by ADAs. The number of participants with treatment emergent (TE) ADA positive samples have been reported as they account for the ADA incidence during the study.

    Time frame: From Day 1 up to Day 211

  22. Evaluation of Positive ADA Titer

    The immunogenicity of AZD3427 as measured by ADAs was evaluated. ADA titer was summarized descriptively as a continuous variable, with median, minimum and maximum values. The antibody titer for the TE-ADA positive (ADA incidence) participants have been reported. It is defined as the sum of treatment-induced ADA (post-baseline positive only) and treatment-boosted ADA. Combined timepoint is used in summary for subject-level overall ADA status (i.e. TE-ADA positive). The summary statistics were calculated based on the maximum post-baseline titre for each ADA-positive subject within each treatment group,'

    Time frame: At Day 1, Day 15, Day 29, Day 85, Day 169 and Day 211.

Other outcomes

  1. Number of Participants With Adverse Events and Serious Adverse Events

    The safety and tolerability of AZD3427 as compared to placebo in participants with HF and PH Group 2 were evaluated. Only treatment emergent adverse events (TEAEs) which had an onset after randomization have been reported here.

    Time frame: From Randomization (Day 1) up to Follow-up Visit (Day 211)

07

Results

Posted Oct 27, 2026

Participant flow

The study was conducted from 24-April-2023 (study start date) to 25-August-2025 (last participant last visit) in 66 study centres across 14 countries; 62 study centres screened participants and of these 52 study centres randomized participants.

Participant flow — Overall Study
MilestoneAZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Started65666365
Completed61595858
Not completed4757
Withdrew: Subject decision2000
Withdrew: Other0020
Withdrew: Physician decision0001
Withdrew: Death0002
Withdrew: Withdrawal by subject0110
Withdrew: Adverse event2624

Outcome measures

PrimaryChange From Baseline in Pulmonary Vascular Resistance (PVR)

The effect of AZD3427 compared with placebo on PVR parameter as measured by right heart catheterization (RHC-a procedure which allows measurement of blood pressure in the right side of the heart) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2 was evaluated. PVR was calculated using formula, PVR=80\* \[Mean pulmonary arterial pressure\[mPAP\](mmHg)- Pulmonary artery wedge pressure\[PAWP\](mmHg)\]/Cardiac output (L/min). Baseline was defined as last non-missing value prior to or on the date of first study intervention dose. PVR was originally measured in dynes·sec/cm⁵. For the statistical analysis, PVR values were log-transformed, and change from baseline was assessed on the log-transformed scale. Results were subsequently back-transformed and presented on the original scale as the ratio of post-baseline to baseline PVR. Therefore, the unit of measure for this endpoint is a ratio. The measure type is geometric mean ratio.

Time frame:
Baseline to Week 25
Reported as:
Geometric mean · Ratio
Change From Baseline in Pulmonary Vascular Resistance (PVR)
RatioAZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Change From Baseline in Pulmonary Vascular Resistance (PVR)1.002 (0.862 to 1.164)1.221 (1.054 to 1.415)0.950 (0.815 to 1.109)1.056 (0.908 to 1.228)
Statistical analysis
  • AZD3427 Dose 1.1 mg vs Placebo · ANCOVA · p = 0.574 (Log transformed ratio to baseline at Week 25 was analysed using an ANCOVA model, with treatment as fixed effect, stratification factor fitted as categorical covariates, and log-transformed baseline measure fitted as a continuous covariate.) · Geometric mean ratio compared to placebo: 0.948 · 95% CI 0.789 to 1.141
  • AZD3427 Dose 5.4 mg vs Placebo · ANCOVA · p = 0.113 (Log transformed ratio to baseline at Week 25 was analysed using an ANCOVA model, with treatment as fixed effect, stratification factor fitted as categorical covariates, and log-transformed baseline measure fitted as a continuous covariate.) · Geometric mean ratio compared to placebo: 1.156 · 95% CI 0.966 to 1.3484
  • AZD3427 Dose 30.0 mg vs Placebo · ANCOVA · p = 0.264 (Log transformed ratio to baseline at Week 25 was analysed using an ANCOVA model, with treatment as fixed effect, stratification factor fitted as categorical covariates, and log-transformed baseline measure fitted as a continuous covariate.) · Geometric mean ratio compared to placebo: 0.900 · 95% CI 0.748 to 1.083
SecondaryChange From Baseline in Mean Pulmonary Arterial Pressure (mPAP)

The effect of AZD3427 compared with placebo on mPAP parameter as measured by RHC after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

Time frame:
Baseline to Week 25
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline in Mean Pulmonary Arterial Pressure (mPAP)
millimeters of mercury (mmHg)AZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Change From Baseline in Mean Pulmonary Arterial Pressure (mPAP)-3.417 (-5.304 to -1.531)-2.005 (-3.892 to -0.119)-2.642 (-4.605 to -0.678)-2.306 (-4.236 to -0.376)
Statistical analysis
  • AZD3427 Dose 1.1 mg vs Placebo · ANCOVA · p = 0.353 · Least square mean difference: -1.111 · 95% CI -3.457 to 1.235Analysis was performed using ANCOVA model with changes in mPAP at week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariate, and baseline fitted as continuous covariate.
  • AZD3427 Dose 5.4 mg vs Placebo · ANCOVA · p = 0.801 · Least square mean difference: 0.301 · 95% CI -2.045 to 2.647Analysis was performed using ANCOVA model with changes in mPAP at week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariate, and baseline fitted as continuous covariate.
  • AZD3427 Dose 30.0 mg vs Placebo · ANCOVA · p = 0.785 · Least square mean difference: -0.335 · 95% CI -2.750 to 2.079Analysis was performed using ANCOVA model with changes in mPAP at week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariate, and baseline fitted as continuous covariate.
SecondaryChange From Baseline in Pulmonary Artery Wedge Pressure (PAWP)

The effect of AZD3427 compared with placebo on PAWP parameter as measured by RHC after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention. PAWP was measured in mmHg. The analysis was done similar to the primary endpoint. Therefore, the unit of measure for this endpoint is a ratio. The measure type is geometric mean ratio.

Time frame:
Baseline to Week 25
Reported as:
Geometric mean · Ratio
Change From Baseline in Pulmonary Artery Wedge Pressure (PAWP)
RatioAZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Change From Baseline in Pulmonary Artery Wedge Pressure (PAWP)0.800 (0.726 to 0.882)0.821 (0.746 to 0.903)0.842 (0.763 to 0.929)0.837 (0.759 to 0.924)
Statistical analysis
  • AZD3427 Dose 1.1 mg vs Placebo · ANCOVA · p = 0.462 · Geometric mean ratio: 0.956 · 95% CI 0.847 to 1.078The analysis was performed using an ANCOVA model, with log changes in PAWP at Week 25 as dependent variable, treatment asfixed effect, stratification factor fitted as categorical covariate, and baseline fitted as a continuous covariate.
  • AZD3427 Dose 5.4 mg vs Placebo · ANCOVA · p = 0.742 · Geometric mean ratio: 0.980 · 95% CI 0.871 to 1.103The analysis was performed using an ANCOVA model, with log changes in PAWP at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariate, and baseline fitted as a continuous covariate.
  • AZD3427 Dose 30.0 mg vs Placebo · ANCOVA · p = 0.922 · Geometric mean ratio: 1.006 · 95% CI 0.892 to 1.134The analysis was performed using an ANCOVA model, with log changes in PAWP at Week 25 as dependent variable, treatment asfixed effect, stratification factor fitted as categorical covariate, and baseline fitted as a continuous covariate.
SecondaryChange From Baseline in Cardiac Output (CO) ECHO

The effect of AZD3427 compared with placebo on CO parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

Time frame:
Baseline to Week 25
Reported as:
Least squares mean · Liter/minute (L/min)
Change From Baseline in Cardiac Output (CO) ECHO
Liter/minute (L/min)AZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Change From Baseline in Cardiac Output (CO) ECHO-0.114 (-0.494 to 0.266)-0.456 (-0.828 to -0.084)-0.429 (-0.805 to -0.052)-0.357 (-0.729 to 0.015)
Statistical analysis
  • AZD3427 Dose 1.1 mg vs Placebo · ANCOVA · p = 0.296 · Ls mean change: 0.243 · 95% CI -0.213 to 0.699Analysis was performed using ANCOVA model, with change in cardiac output at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline cardiac output fitted as continuous covariate.
  • AZD3427 Dose 5.4 mg vs Placebo · ANCOVA · p = 0.669 · Ls mean change: -0.099 · 95% CI -0.555 to 0.356Analysis was performed using ANCOVA model, with change in cardiac output at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline cardiac output fitted as continuous covariate.
  • AZD3427 Dose 30.0 mg vs Placebo · ANCOVA · p = 0.765 · Ls mean change: -0.072 · 95% CI -0.542 to 0.399Analysis was performed using ANCOVA model, with change in cardiac output at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline cardiac output fitted as continuous covariate.
SecondaryChange From Baseline in Left Ventricular Stroke Volume (LV SV)

The effect of AZD3427 compared with placebo on LV SV parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

Time frame:
Baseline to Week 25
Reported as:
Least squares mean · milliliters (mL)
Change From Baseline in Left Ventricular Stroke Volume (LV SV)
milliliters (mL)AZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Change From Baseline in Left Ventricular Stroke Volume (LV SV)-5.512 (-9.905 to -1.119)-8.986 (-13.345 to -4.628)-7.605 (-11.975 to -3.235)-6.903 (-11.140 to -2.667)
Statistical analysis
  • AZD3427 Dose 1.1 mg vs Placebo · ANCOVA · p = 0.603 · Ls mean change: 1.392 · 95% CI -3.848 to 6.631Analysis was performed using an ANCOVA model, with change in LV SV at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline LVSV fitted as continuous covariate.
  • AZD3427 Dose 5.4 mg vs Placebo · ANCOVA · p = 0.443 · Ls mean change: -2.083 · 95% CI -7.405 to 3.239Analysis was performed using an ANCOVA model, with change in LV SV at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline LVSV fitted as continuous covariate.
  • AZD3427 Dose 30.0 mg vs Placebo · ANCOVA · p = 0.794 · Ls mean change: -0.702 · 95% CI -5.968 to 4.564Analysis was performed using an ANCOVA model, with change in LV SV at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline LVSV fitted as continuous covariate.
SecondaryChange From Baseline in Left Ventricular Ejection Fraction (LVEF)

The effect of AZD3427 compared with placebo on EF parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

Time frame:
Baseline to Week 25
Reported as:
Least squares mean · Percentage
Change From Baseline in Left Ventricular Ejection Fraction (LVEF)
PercentageAZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Change From Baseline in Left Ventricular Ejection Fraction (LVEF)0.122 (-1.459 to 1.703)-0.046 (-1.652 to 1.559)0.074 (-1.596 to 1.744)-0.389 (-1.968 to 1.190)
Statistical analysis
  • AZD3427 Dose 1.1 mg vs Placebo · ANCOVA · p = 0.607 · Ls mean change: 0.511 · 95% CI -1.434 to 2.456Analysis was performed using an ANCOVA model, with change in LVEF at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline LVEF fitted as a continuous covariate.
  • AZD3427 Dose 5.4 mg vs Placebo · ANCOVA · p = 0.733 · Ls mean change: 0.343 · 95% CI -1.625 to 2.310Analysis was performed using an ANCOVA model, with change in LVEF at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline LVEF fitted as a continuous covariate.
  • AZD3427 Dose 30.0 mg vs Placebo · ANCOVA · p = 0.657 · Ls mean change: 0.463 · 95% CI -1.577 to 2.502Analysis was performed using an ANCOVA model, with change in LVEF at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline LVEF fitted as a continuous covariate.
SecondaryChange From Baseline in Left Ventricular Global Longitudinal Strain (LVGLS)

The effect of AZD3427 compared with placebo on LVGLS parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. LVGLS is measured by echocardiograohy. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

Time frame:
Baseline to Week 25
Reported as:
Least squares mean · Percentage
Change From Baseline in Left Ventricular Global Longitudinal Strain (LVGLS)
PercentageAZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Change From Baseline in Left Ventricular Global Longitudinal Strain (LVGLS)0.658 (-0.301 to 1.618)0.476 (-0.522 to 1.475)0.252 (-0.706 to 1.210)0.904 (-0.047 to 1.854)
Statistical analysis
  • AZD3427 Dose 1.1 mg vs Placebo · ANCOVA · p = 0.689 · Ls mean change: -0.245 · 95% CI -1.447 to 0.957Analysis was performed using ANCOVA model, with changes in LV GLS parameters at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline ECHO parameters fitted as continuous covariate.
  • AZD3427 Dose 5.4 mg vs Placebo · ANCOVA · p = 0.492 · Ls mean change: -0.427 · 95% CI -1.647 to 0.792Analysis was performed using ANCOVA model, with changes in LV GLS parameters at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline ECHO parameters fitted as continuous covariate.
  • AZD3427 Dose 30.0 mg vs Placebo · ANCOVA · p = 0.281 · Ls mean change: -0.651 · 95% CI -1.836 to 0.5334Analysis was performed using ANCOVA model, with changes in LV GLS parameters at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline ECHO parameters fitted as continuous covariate.
SecondaryChange From Baseline in Pulmonary Arterial Systolic Pressure (PASP)

The effect of AZD3427 compared with placebo on PASP parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

Time frame:
Baseline to Week 25
Reported as:
Least squares mean · mmHg
Change From Baseline in Pulmonary Arterial Systolic Pressure (PASP)
mmHgAZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Change From Baseline in Pulmonary Arterial Systolic Pressure (PASP)-0.608 (-4.267 to 3.051)-3.609 (-7.576 to 0.357)-1.943 (-5.766 to 1.880)-0.962 (-4.993 to 3.070)
Statistical analysis
  • AZD3427 Dose 1.1 mg vs Placebo · ANCOVA · p = 0.889 · Ls mean change: 0.353 · 95% CI -4.606 to 5.312The analysis was performed using an ANCOVA model, with changes in PASP at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline ECHO parameters fitted as a continuous covariate
  • AZD3427 Dose 5.4 mg vs Placebo · ANCOVA · p = 0.331 · Ls mean change: -2.648 · 95% CI -7.994 to 2.698The analysis was performed using an ANCOVA model, with changes in PASP at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline ECHO parameters fitted as a continuous covariate
  • AZD3427 Dose 30.0 mg vs Placebo · ANCOVA · p = 0.705 · Ls mean change: -0.981 · 95% CI -6.071 to 4.109The analysis was performed using an ANCOVA model, with changes in PASP at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline ECHO parameters fitted as a continuous covariate.
SecondaryChange From Baseline in Right Ventricle/Left Ventricle (RV/LV) Ratio

The effect of AZD3427 compared with placebo on RV/LV parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

Time frame:
Baseline to Week 25
Reported as:
Least squares mean · Ratio
Change From Baseline in Right Ventricle/Left Ventricle (RV/LV) Ratio
RatioAZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Change From Baseline in Right Ventricle/Left Ventricle (RV/LV) Ratio-0.003 (-0.032 to 0.026)-0.030 (-0.059 to 0.000)-0.026 (-0.055 to 0.004)-0.018 (-0.047 to 0.012)
Statistical analysis
  • AZD3427 Dose 1.1 mg vs Placebo · ANCOVA · p = 0.434 · Ls mean change: 0.014 · 95% CI -0.022 to 0.050The analysis was performed using an ANCOVA model with changes in RV/LV ratio at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline RV/LV ratio fitted as continuous covariate.
  • AZD3427 Dose 5.4 mg vs Placebo · ANCOVA · p = 0.518 · Ls mean change: -0.012 · 95% CI -0048 to 0.024The analysis was performed using an ANCOVA model with changes in RV/LV ratio at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline RV/LV ratio fitted as continuous covariate.
  • AZD3427 Dose 30.0 mg vs Placebo · ANCOVA · p = 0.665 · Ls mean change: -0.008 · 95% CI -0.044 to 0.028The analysis was performed using an ANCOVA model with changes in RV/LV ratio at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline RV/LV ratio fitted as continuous covariate.
SecondaryChange From Baseline in Right Ventricular Outflow Tract Acceleration Time (RVOT AT)

The effect of AZD3427 compared with placebo on RVOT AT parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

Time frame:
Baseline to Week 25
Reported as:
Least squares mean · milliseconds (ms)
Change From Baseline in Right Ventricular Outflow Tract Acceleration Time (RVOT AT)
milliseconds (ms)AZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Change From Baseline in Right Ventricular Outflow Tract Acceleration Time (RVOT AT)-7.042 (-18.193 to 4.108)-0.409 (-11.934 to 11.115)3.346 (-8.294 to 14.987)-3.481 (-14.131 to 7.169)
Statistical analysis
  • AZD3427 Dose 1.1 mg vs Placebo · ANCOVA · p = 0.596 · Ratio: -3.561 · 95% CI -16.721 to 9.599Analysis was performed using an ANCOVA model, with changes in RVOT AT at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline RVOT AT fitted as a continuous covariate.
  • AZD3427 Dose 5.4 mg vs Placebo · ANCOVA · p = 0.658 · Ratio: 3.072 · 95% CI -10.530 to 16.674Analysis was performed using an ANCOVA model, with changes in RVOT AT at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline RVOT AT fitted as a continuous covariate.
  • AZD3427 Dose 30.0 mg vs Placebo · ANCOVA · p = 0.330 · Ratio: 6.828 · 95% CI -6.927 to 20.583Analysis was performed using an ANCOVA model, with changes in RVOT AT at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline RVOT AT fitted as a continuous covariate.
SecondaryChange From Baseline in Tricuspid Regurgitation Velocity (TRV)

The effect of AZD3427 compared with placebo on TRV parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. TRV was measured by Echocardiography. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

Time frame:
Baseline to Week 25
Reported as:
Least squares mean · centimeter/second (cm/s)
Change From Baseline in Tricuspid Regurgitation Velocity (TRV)
centimeter/second (cm/s)AZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Change From Baseline in Tricuspid Regurgitation Velocity (TRV)-0.850 (-13.947 to 12.247)-10.512 (-24.468 to 3.445)-6.110 (-20.022 to 7.802)0.859 (-13.700 to 15.418)
Statistical analysis
  • AZD3427 Dose 1.1 mg vs Placebo · ANCOVA · p = 0.853 · Ls mean change: -1.709 · 95% CI -19.832 to 16.415The analysis is performed using an ANCOVA model, with changes in TRV at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline TRV fitted as a continuous covariate.
  • AZD3427 Dose 5.4 mg vs Placebo · ANCOVA · p = 0.248 · Ls mean change: -11.370 · 95% CI -30.681 to 7.940The analysis is performed using an ANCOVA model, with changes in TRV at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline TRV fitted as a continuous covariate.
  • AZD3427 Dose 30.0 mg vs Placebo · ANCOVA · p = 0.456 · Ls mean change: -6.968 · 95% CI -25.311 to 11.374The analysis is performed using an ANCOVA model, with changes in TRV at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline TRV fitted as a continuous covariate.
SecondaryChange From Baseline in TAPSE/PASP [Tricuspid Annular Plane Systolic Excursion/ Pulmonary Arterial Systolic Pressure]

The effect of AZD3427 compared with placebo on TAPSE/PASP parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

Time frame:
Baseline to Week 25
Reported as:
Least squares mean · cm/mmHg
Change From Baseline in TAPSE/PASP [Tricuspid Annular Plane Systolic Excursion/ Pulmonary Arterial Systolic Pressure]
cm/mmHgAZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Change From Baseline in TAPSE/PASP [Tricuspid Annular Plane Systolic Excursion/ Pulmonary Arterial Systolic Pressure]0.002 (-0.005 to 0.009)0.004 (-0.002 to 0.011)0.000 (-0.006 to 0.007)0.005 (-0.002 to 0.012)
Statistical analysis
  • AZD3427 Dose 1.1 mg vs Placebo · ANCOVA · p = 0.513 · Ls mean change: -0.003 · 95% CI -0.012 to 0.006The analysis was performed using an ANCOVA model, with changes in TAPSE/PASP at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline TAPSE/PASP fitted as a continuous covariate.
  • AZD3427 Dose 5.4 mg vs Placebo · ANCOVA · p = 0.850 · Ls mean change: -0.001 · 95% CI -0.010 to 0.008The analysis was performed using an ANCOVA model, with changes in TAPSE/PASP at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline TAPSE/PASP fitted as a continuous covariate.
  • AZD3427 Dose 30.0 mg vs Placebo · ANCOVA · p = 0.284 · Ls mean change: -0.005 · 95% CI -0.014 to 0.004The analysis was performed using an ANCOVA model, with changes in TAPSE/PASP at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline TAPSE/PASP fitted as a continuous covariate.
SecondaryChange From Baseline in Systemic Vascular Resistance (SVR)

The effect of AZD3427 compared with placebo on systemic vascular resistance parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. SVR was measured by Echocardipgraphy. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

Time frame:
Baseline to Week 25
Reported as:
Least squares mean · dynes*s*cm^-5
Change From Baseline in Systemic Vascular Resistance (SVR)
dynes*s*cm^-5AZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Change From Baseline in Systemic Vascular Resistance (SVR)-1.968 (-166.324 to 162.388)34.970 (-138.860 to 208.801)60.014 (-109.154 to 229.183)97.933 (-68.521 to 264.388)
Statistical analysis
  • AZD3427 Dose 1.1 mg vs Placebo · ANCOVA · p = 0.342 · Ratio: -99.901 · 95% CI -305.850 to 106.047Analysis was performed using ANCOVA model, with changes in SVR at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline SVR fitted as continuous covariate.
  • AZD3427 Dose 5.4 mg vs Placebo · ANCOVA · p = 0.567 · Ratio: -62.963 · 95% CI -278.365 to 152.438Analysis was performed using ANCOVA model, with changes in SVR at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline SVR fitted as continuous covariate.
  • AZD3427 Dose 30.0 mg vs Placebo · ANCOVA · p = 0.730 · Ratio: -37.919 · 95% CI -252.978 to 177.140Analysis was performed using ANCOVA model, with changes in SVR at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariates and baseline SVR fitted as continuous covariate.
SecondaryChange From Baseline in 6-minute Walking Distance (6MWD)

The effect of AZD3427 compared with placebo on function and symptoms using 6MWD parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

Time frame:
Baseline to Week 25
Reported as:
Least squares mean · meter (m)
Change From Baseline in 6-minute Walking Distance (6MWD)
meter (m)AZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Change From Baseline in 6-minute Walking Distance (6MWD)2.299 (-19.504 to 24.102)6.092 (-15.819 to 28.003)7.791 (-14.383 to 29.966)15.195 (-6.949 to 37.340)
Statistical analysis
  • AZD3427 Dose 1.1 mg vs Placebo · ANCOVA · p = 0.342 (The analysis is performed using an ANCOVA model, with mean changes in 6MWD at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariate, and baseline 6MWD fitted as a continuous covariate.) · Least squares mean change: -12.896 · 95% CI -39.474 to 13.682
  • AZD3427 Dose 5.4 mg vs Placebo · ANCOVA · p = 0.507 (The analysis is performed using an ANCOVA model, with mean changes in 6MWD at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariate, and baseline 6MWD fitted as a continuous covariate.) · Least squares mean change: -9.103 · 95% CI -35.976 to 17.769
  • AZD3427 Dose 30.0 mg vs Placebo · ANCOVA · p = 0.590 (The analysis is performed using an ANCOVA model, with mean changes in 6MWD at Week 25 as dependent variable, treatment as fixed effect, stratification factor fitted as categorical covariate, and baseline 6MWD fitted as a continuous covariate.) · Least squares mean change: -7.404 · 95% CI -34.368 to 19.561
SecondaryChange From Baseline in Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ TSS)

The effect of AZD3427 compared with placebo on function and symptoms using KCCQ TSS parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. The score ranged from 0 to 100, where a higher score represents a better patient outcome. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

Time frame:
Baseline to Week 25
Reported as:
Mean · Score on scale
Change From Baseline in Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ TSS)
Score on scaleAZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Change From Baseline in Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ TSS)6.45 ± 19.0210.20 ± 18.209.98 ± 18.765.12 ± 18.81
SecondaryNumber of Participants With Improved Change From Baseline in New York Heart Association Functional Class (NYHA FC)

The effect of AZD3427 compared with placebo on function and symptoms using NYHA FC parameter after 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

Time frame:
Baseline to Week 25
Reported as:
Count of participants · Participants
Number of Participants With Improved Change From Baseline in New York Heart Association Functional Class (NYHA FC)
ParticipantsAZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Number of Participants With Improved Change From Baseline in New York Heart Association Functional Class (NYHA FC)16161420
SecondaryChange From Baseline in Serum Creatinine

The effect of AZD3427 compared with placebo using serum creatinine parameter after 12 and 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention. Creatinine was measured in micromoles/liter. The analysis was done similar to the primary endpoint. Therefore, the unit of measure for this endpoint is a ratio.

Time frame:
Baseline to Week 13 and Week 25
Reported as:
Geometric least squares mean · Ratio
Change From Baseline in Serum Creatinine
RatioAZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Week 131.003 (0.956 to 1.052)1.002 (0.955 to 1.051)0.962 (0.915 to 1.010)1.055 (1.005 to 1.108)
Week 250.984 (0.936 to 1.035)1.015 (0.963 to 1.069)0.968 (0.919 to 1.021)1.071 (1.012 to 1.133)
SecondaryChange From Baseline in N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP)

The effect of AZD3427 compared with placebo using NT-proBNP parameter after 12 and 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention. NT-ProBNP was measured in picomole/Liter. The analysis was done similar to the primary endpoint. Therefore, the unit of measure for this endpoint is a ratio.

Time frame:
Baseline to Week 13 and Week 25
Reported as:
Geometric least squares mean · Ratio
Change From Baseline in N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP)
RatioAZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Week 131.046 (0.914 to 1.196)1.051 (0.917 to 1.203)1.013 (0.884 to 1.162)0.955 (0.832 to 1.095)
Week 250.966 (0.806 to 1.159)1.109 (0.920 to 1.336)0.988 (0.820 to 1.189)1.047 (0.863 to 1.270)
SecondaryChange From Baseline in Cystatin C

The effect of AZD3427 compared with placebo using cystatin C parameter after 12 and 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention. Cystatin C was measured in milligram/deciliter. The analysis was done similar to the primary endpoint. Therefore, the unit of measure for this endpoint is a ratio.

Time frame:
Baseline to Week 13 and Week 25
Reported as:
Geometric least squares mean · Ratio
Change From Baseline in Cystatin C
RatioAZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Week 130.983 (0.938 to 1.030)1.015 (0.970 to 1.062)0.988 (0.941 to 1.036)1.002 (0.956 to 1.050)
Week 250.972 (0.921 to 1.026)1.013 (0.961 to 1.069)0.990 (0.936 to 1.047)1.039 (0.982 to 1.100)
SecondaryChange From Baseline in eGFR (Estimated Glomerular Filtration Rate)

The effect of AZD3427 compared with placebo using eGFR parameter after 12 and 24 weeks of treatment in participants with HF and PH Group 2 was evaluated. Baseline was defined as the last non-missing value prior to or on the same date as the administration of the first dose of study intervention.

Time frame:
Baseline to Week 13 and Week 25
Reported as:
Least squares mean · mL/minute/1.73 m^2 (mL/min/1.73 m^2)
Change From Baseline in eGFR (Estimated Glomerular Filtration Rate)
mL/minute/1.73 m^2 (mL/min/1.73 m^2)AZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Week 130.840 (-1.992 to 3.672)-0.638 (-3.474 to 2.198)2.112 (-0.799 to 5.024)-2.323 (-5.244 to 0.599)
Week 251.355 (-1.755 to 4.466)-1.380 (-4.488 to 1.727)1.636 (-1.562 to 4.8344)-3.771 (-7.191 to -0.352)
SecondaryAZD3427 Serum Concentration

Serum concentration of AZD3427 was summarised by timepoints and dose level. This was done to evaluate the pharmacokinetics (PK) of AZD3427 after dosing in participants with HF and PH Group 2. Considering the approximately 13-14 days half-life of AZD3427, low or non-quantifiable serum concentrations at Week 31 are not unexpected. Therefore, the presentation of the Week 31 results, including the reported NA values, reflects the prespecified statistical handling of the data and the observed concentration profile.

Time frame:
On Week 3, Week 5, Week 13, Week 19, Week 25 and Week 31
Reported as:
Geometric mean · microgram/Liter (ug/L )
AZD3427 Serum Concentration
microgram/Liter (ug/L )AZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mg
Week 350.27 ± 70.38143.2 ± 53.93501.9 ± 45.04
Week 560.94 ± 72.99191.5 ± 68.93658.3 ± 56.19
Week 1376.38 ± 80.85214.1 ± 84.42754.3 ± 83.59
Week 1980.5 ± 68.96191.0 ± 83.70786.4 ± 89.92
Week 2586.41 ± 71.99250.8 ± 81.65849.0 ± 78.64
Week 31NA ± NA23.12 ± 83.6460.18 ± 126.2
SecondaryNumber of Participants With Presence of Anti-drug Antibodies (ADAs)

The immunogenicity of AZD3427 was evaluated as measured by ADAs. The number of participants with treatment emergent (TE) ADA positive samples have been reported as they account for the ADA incidence during the study.

Time frame:
From Day 1 up to Day 211
Reported as:
Number · Count of participants
Number of Participants With Presence of Anti-drug Antibodies (ADAs)
Count of participantsAZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Number of Participants With Presence of Anti-drug Antibodies (ADAs)39161
SecondaryEvaluation of Positive ADA Titer

The immunogenicity of AZD3427 as measured by ADAs was evaluated. ADA titer was summarized descriptively as a continuous variable, with median, minimum and maximum values. The antibody titer for the TE-ADA positive (ADA incidence) participants have been reported. It is defined as the sum of treatment-induced ADA (post-baseline positive only) and treatment-boosted ADA. Combined timepoint is used in summary for subject-level overall ADA status (i.e. TE-ADA positive). The summary statistics were calculated based on the maximum post-baseline titre for each ADA-positive subject within each treatment group,'

Time frame:
At Day 1, Day 15, Day 29, Day 85, Day 169 and Day 211.
Reported as:
Median · Titer
Evaluation of Positive ADA Titer
TiterAZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Evaluation of Positive ADA Titer50 (50 to 100)50 (50 to 400)150 (50 to 3200)NA (400 to 400)
Other pre-specifiedNumber of Participants With Adverse Events and Serious Adverse Events

The safety and tolerability of AZD3427 as compared to placebo in participants with HF and PH Group 2 were evaluated. Only treatment emergent adverse events (TEAEs) which had an onset after randomization have been reported here.

Time frame:
From Randomization (Day 1) up to Follow-up Visit (Day 211)
Reported as:
Number · Count of participants
Number of Participants With Adverse Events and Serious Adverse Events
Count of participantsAZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Any adverse event (AE)47475046
Any serious adverse event (SAE)10131017
Any SAE with outcome death1203
Any AE leading to discontinuation of Investigational Product (IP)2634
Any AE leading to withdrawal from study1433

Adverse events

Collected over Until follow up visit (Day 211). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AZD3427 Dose 1.1 mg1/65 (1.5%)11/65 (16.9%)28/65 (43.1%)
AZD3427 Dose 5.4 mg2/66 (3%)14/66 (21.2%)22/66 (33.3%)
AZD3427 Dose 30.0 mg0/63 (0%)10/63 (15.9%)29/63 (46%)
Placebo3/65 (4.6%)17/65 (26.2%)23/65 (35.4%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
EventAZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
Cardiac failureCardiac disorders4/656/661/637/65
PneumoniaInfections and infestations1/650/661/633/65
Cardiac failure congestiveCardiac disorders0/650/662/630/65
Cardiac arrestCardiac disorders0/650/660/632/65
Ventricular tachycardiaCardiac disorders0/650/660/632/65
AnaemiaBlood and lymphatic system disorders1/652/661/630/65
Cardiac failure acuteCardiac disorders0/652/661/631/65
CellulitisInfections and infestations0/650/661/630/65
DiverticulitisInfections and infestations0/650/661/630/65
Pneumonia bacterialInfections and infestations0/650/661/630/65
Most frequent other events
Showing 10 of 13
Most frequent other events
EventAZD3427 Dose 1.1 mgAZD3427 Dose 5.4 mgAZD3427 Dose 30.0 mgPlacebo
HypotensionVascular disorders6/654/667/632/65
Oedema peripheralGeneral disorders3/654/666/635/65
Upper respiratory tract infectionInfections and infestations6/652/665/631/65
DyspnoeaRespiratory, thoracic and mediastinal disorders5/656/664/632/65
Urinary tract infectionInfections and infestations4/653/665/633/65
Cardiac failureCardiac disorders5/651/665/634/65
NasopharyngitisInfections and infestations1/653/663/635/65
Pain in extremityMusculoskeletal and connective tissue disorders5/652/660/631/65
HypokalaemiaMetabolism and nutrition disorders2/654/664/631/65
FallInjury, poisoning and procedural complications2/652/664/630/65

Baseline characteristics

The Full Analysis Set consisted of all participants who were randomized and had received at least one dose of study intervention.

Age, Continuous
Age, Continuous(Years)AZD3427 1.1 mgAZD3427 5.4 mgAZD3427 30.0 mgPlaceboTotal
Mean71.2 ± 13.370.2 ± 13.269.2 ± 14.066.5 ± 12.469.3 ± 13.3
Sex: Female, Male
Sex: Female, Male(Participants)AZD3427 1.1 mgAZD3427 5.4 mgAZD3427 30.0 mgPlaceboTotal
Female31383428131
Male34282937128
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AZD3427 1.1 mgAZD3427 5.4 mgAZD3427 30.0 mgPlaceboTotal
White54515255212
American Indian or Alaska Native00000
Asian798731
Black or African American25209
Hawaiian Native or Other Pacific Islander00000
Other00011
Not Reported21126
08

Study locations

60 sites
  • Research Site
    Beverly Hills, California 90211, United States
  • Research Site
    La Jolla, California 92093, United States
  • Research Site
    New Haven, Connecticut 06519, United States
  • Research Site
    Baltimore, Maryland 21287, United States
  • Research Site
    St Louis, Missouri 63136, United States
  • Research Site
    Omaha, Nebraska 68198, United States
  • Research Site
    Rock Hill, South Carolina 29732, United States
  • Research Site
    Linz, 4020, Austria
  • Research Site
    Vienna, 1100, Austria
  • Research Site
    Edmonton, Alberta T6G 2E1, Canada
  • Research Site
    Vancouver, British Columbia V6Z 1Y6, Canada
  • Research Site
    Halifax, Nova Scotia B3H 3A7, Canada
  • Research Site
    London, Ontario N6A 5A5, Canada
  • Research Site
    Ottawa, Ontario K1Y 4W7, Canada
  • Research Site
    Toronto, Ontario M5G 2N2, Canada
  • Research Site
    Montreal, Quebec H1T 1C8, Canada
  • Research Site
    Beijing, 100034, China
  • Research Site
    Changsha, 430033, China
  • Research Site
    Guangzhou, 510100, China
  • Research Site
    Kunming, 650051, China
  • Research Site
    Prague, 10034, Czechia
  • Research Site
    Prague, 12808, Czechia
  • Research Site
    Prague, 140 21, Czechia
  • Research Site
    Aarhus, 8200, Denmark
  • Research Site
    Copenhagen, 2100, Denmark
  • Research Site
    Berlin, 13353, Germany
  • Research Site
    Cologne, 50937, Germany
  • Research Site
    Frankfurt, 60596, Germany
  • Research Site
    Jena, 07747, Germany
  • Research Site
    Brescia, 25123, Italy
  • Research Site
    Genoa, 16132, Italy
  • Research Site
    Marche, 60126, Italy
  • Research Site
    Milan, 20138, Italy
  • Research Site
    Milan, 20142, Italy
  • Research Site
    Trieste, 34149, Italy
  • Research Site
    Bunkyō City, 113-8603, Japan
  • Research Site
    Kasugai-shi, 487-0016, Japan
  • Research Site
    Kure-shi, 737-8505, Japan
  • Research Site
    Nagoya, 466-8560, Japan
  • Research Site
    Sapporo, 060-8648, Japan
  • Research Site
    Sunto-gun, 411-8611, Japan
  • Research Site
    Toyama, 930-0194, Japan
  • Research Site
    Deventer, 7416 SE, Netherlands
  • Research Site
    Heerlen, 6419 PC, Netherlands
  • Research Site
    Tilburg, 5022 GC, Netherlands
  • Research Site
    Bialystok, 15-276, Poland
  • Research Site
    Gdansk, 80-952, Poland
  • Research Site
    Krakow, 31-202, Poland
  • Research Site
    Warsaw, 02-005, Poland
  • Research Site
    Warsaw, 04-628, Poland
  • Research Site
    Wroclaw, 50-556, Poland
  • Research Site
    Majadahonda, 28222, Spain
  • Research Site
    Seville, 41009, Spain
  • Research Site
    Toledo, 45007, Spain
  • Research Site
    Valencia, 46026, Spain
  • Research Site
    Gothenburg, 413 45, Sweden
  • Research Site
    Huddinge, 141 57, Sweden
  • Research Site
    Cambridge, CB2 0AY, United Kingdom
  • Research Site
    Clydebank, G81 4DY, United Kingdom
  • Research Site
    London, SW3 6NP, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Jul 2025, 26 months.

Results were first posted in Oct 2026, 1 year 3 months after primary completion.

Of 50 phase 2 interventional studies under Hypertension, Pulmonary, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 71. This study's 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2023
First posted
Feb 21, 2023
StartActual
Apr 24, 2023
Primary completionActual
Jul 15, 2025
CompletionActual
Aug 25, 2025
Results first posted
Oct 27, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 27, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange from baselineFrom Baseline in Pulmonary Vascular Resistance (PVR)Time frame: Baseline to Week 25
Oct 27, 2026
Documents
Secondary outcomes
23 edited
What changed in the outcomes
  • EditedChange from baselineFrom Baseline in Mean pulmonary arterial pressurePulmonary Arterial Pressure (mPAP)Time frame: Baseline to Week 25
  • EditedChange from baselineFrom Baseline in Pulmonary artery wedge pressureArtery Wedge Pressure (PAWP)Time frame: Baseline to Week 25
  • EditedChange from baselineFrom Baseline in cardiac outputCardiac Output (CO) ECHOTime frame: Baseline to Week 25
  • EditedChange from baselineFrom Baseline in Left Ventricular Stroke Volume (LV SV)Time frame: Baseline to Week 25
  • EditedChange from baselineFrom Baseline in Left Ventricular Ejection fractionFraction (EFLVEF)Time frame: Baseline to Week 25
  • EditedChange from baselineFrom Baseline in left ventricular global longitudinal strainLeft Ventricular Global Longitudinal Strain (LVGLS)Time frame: Baseline to Week 25
  • EditedChange from baselineFrom Baseline in pulmonary arterial systolic pressurePulmonary Arterial Systolic Pressure (PASP)Time frame: Baseline to Week 25
  • EditedChange from baselineFrom Baseline in right ventricleRight Ventricle/left ventricleLeft Ventricle (RV/LV) ratioRatioTime frame: Baseline to Week 25
  • EditedChange from baselineFrom Baseline in right ventricular outflow tract acceleration timeRight Ventricular Outflow Tract Acceleration Time (RVOT AT)Time frame: Baseline to Week 25
  • EditedChange from baselineFrom Baseline in Tricuspid regurgitation velocityRegurgitation Velocity (TRV)Time frame: Baseline to Week 25
  • EditedChange from baselineFrom Baseline in TAPSE/PASP [Tricuspid annular plane systolic excursionAnnular Plane Systolic Excursion/ Pulmonary arterial systolic pressureArterial Systolic Pressure]Time frame: Baseline to Week 25
  • EditedChange from baselineFrom Baseline in systemic vascular resistanceSystemic Vascular Resistance (SVR)Time frame: Baseline to Week 25
  • EditedChange from baselineFrom Baseline in 6-minute walking distanceWalking Distance (6MWD)Time frame: Baseline to Week 25
  • EditedChange from baselineFrom Baseline in Kansas City Cardiomyopathy Questionnaire total symptom scoreTotal Symptom Score (KCCQ TSS)Time frame: Baseline to Week 25
  • EditedNumber of Participants With Improved Change from baselineFrom Baseline in New York Heart Association Functional Class (NYHA FC)Time frame: Baseline to Week 25
  • EditedChange from baselineFrom Baseline in serum creatinineSerum CreatinineTime frame: Baseline to Week 13 and Week 25
  • EditedChange from baselineFrom Baseline in N-terminal prohormoneProhormone of brain natriuretic peptideBrain Natriuretic Peptide (NT-proBNP)Time frame: Baseline to Week 13 and Week 25
  • EditedChange from baselineFrom Baseline in cystatinCystatin CTime frame: Baseline to Week 13 and Week 25
  • EditedChange from baselineFrom Baseline in eGFR (estimated glomerular filtration rateEstimated Glomerular Filtration Rate)Time frame: Baseline to Week 13 and Week 25
  • EditedNumber of participants with presenceParticipants With Presence of Anti-drug antibodiesAntibodies (ADAs)Time frame: On Day 1, Day 15, Day 29, Day 85, Day 169, and Day 211 → From Day 1 up to Day 211
  • EditedEvaluation of positivePositive ADA titerTiterTime frame: On Day 1, Day 15, Day 29, Day 85, Day 169, and Day 211 → At Day 1, Day 15, Day 29, Day 85, Day 169 and Day 211.
  • ChangedBefore Pharmacokinetics (AZD3427 serum exposure)Now AZD3427 Serum ConcentrationTime frame: On Day 15, Day 29, Day 85, Day 127, Day 169, and Day 211 → On Week 3, Week 5, Week 13, Week 19, Week 25 and Week 31
  • Editedother outcomeNumber of participants with adverse eventsParticipants With Adverse Events and serious adverse eventsSerious Adverse EventsTime frame: From Randomization (Day 1) up to Follow-up Visit (Day 211)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange from baselineFrom Baseline in Pulmonary Vascular Resistance (PVR)Time frame: Baseline to Week 25
    Secondary outcomes 23 edited
    What changed in the outcomes
    • EditedChange from baselineFrom Baseline in Mean pulmonary arterial pressurePulmonary Arterial Pressure (mPAP)Time frame: Baseline to Week 25
    • EditedChange from baselineFrom Baseline in Pulmonary artery wedge pressureArtery Wedge Pressure (PAWP)Time frame: Baseline to Week 25
    • EditedChange from baselineFrom Baseline in cardiac outputCardiac Output (CO) ECHOTime frame: Baseline to Week 25
    • EditedChange from baselineFrom Baseline in Left Ventricular Stroke Volume (LV SV)Time frame: Baseline to Week 25
    • EditedChange from baselineFrom Baseline in Left Ventricular Ejection fractionFraction (EFLVEF)Time frame: Baseline to Week 25
    • EditedChange from baselineFrom Baseline in left ventricular global longitudinal strainLeft Ventricular Global Longitudinal Strain (LVGLS)Time frame: Baseline to Week 25
    • EditedChange from baselineFrom Baseline in pulmonary arterial systolic pressurePulmonary Arterial Systolic Pressure (PASP)Time frame: Baseline to Week 25
    • EditedChange from baselineFrom Baseline in right ventricleRight Ventricle/left ventricleLeft Ventricle (RV/LV) ratioRatioTime frame: Baseline to Week 25
    • EditedChange from baselineFrom Baseline in right ventricular outflow tract acceleration timeRight Ventricular Outflow Tract Acceleration Time (RVOT AT)Time frame: Baseline to Week 25
    • EditedChange from baselineFrom Baseline in Tricuspid regurgitation velocityRegurgitation Velocity (TRV)Time frame: Baseline to Week 25
    • EditedChange from baselineFrom Baseline in TAPSE/PASP [Tricuspid annular plane systolic excursionAnnular Plane Systolic Excursion/ Pulmonary arterial systolic pressureArterial Systolic Pressure]Time frame: Baseline to Week 25
    • EditedChange from baselineFrom Baseline in systemic vascular resistanceSystemic Vascular Resistance (SVR)Time frame: Baseline to Week 25
    • EditedChange from baselineFrom Baseline in 6-minute walking distanceWalking Distance (6MWD)Time frame: Baseline to Week 25
    • EditedChange from baselineFrom Baseline in Kansas City Cardiomyopathy Questionnaire total symptom scoreTotal Symptom Score (KCCQ TSS)Time frame: Baseline to Week 25
    • EditedNumber of Participants With Improved Change from baselineFrom Baseline in New York Heart Association Functional Class (NYHA FC)Time frame: Baseline to Week 25
    • EditedChange from baselineFrom Baseline in serum creatinineSerum CreatinineTime frame: Baseline to Week 13 and Week 25
    • EditedChange from baselineFrom Baseline in N-terminal prohormoneProhormone of brain natriuretic peptideBrain Natriuretic Peptide (NT-proBNP)Time frame: Baseline to Week 13 and Week 25
    • EditedChange from baselineFrom Baseline in cystatinCystatin CTime frame: Baseline to Week 13 and Week 25
    • EditedChange from baselineFrom Baseline in eGFR (estimated glomerular filtration rateEstimated Glomerular Filtration Rate)Time frame: Baseline to Week 13 and Week 25
    • EditedNumber of participants with presenceParticipants With Presence of Anti-drug antibodiesAntibodies (ADAs)Time frame: On Day 1, Day 15, Day 29, Day 85, Day 169, and Day 211 → From Day 1 up to Day 211
    • EditedEvaluation of positivePositive ADA titerTiterTime frame: On Day 1, Day 15, Day 29, Day 85, Day 169, and Day 211 → At Day 1, Day 15, Day 29, Day 85, Day 169 and Day 211.
    • ChangedBefore Pharmacokinetics (AZD3427 serum exposure)Now AZD3427 Serum ConcentrationTime frame: On Day 15, Day 29, Day 85, Day 127, Day 169, and Day 211 → On Week 3, Week 5, Week 13, Week 19, Week 25 and Week 31
    • Editedother outcomeNumber of participants with adverse eventsParticipants With Adverse Events and serious adverse eventsSerious Adverse EventsTime frame: From Randomization (Day 1) up to Follow-up Visit (Day 211)
    + 3 other changes: verification date, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05737940
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Feb 21, 2023
Start date
Apr 24, 2023
Primary completion
Jul 15, 2025
Completion
Aug 25, 2025
Results posted
Oct 27, 2026
Last update
Oct 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD3427

Start the discussion